|Systematic (IUPAC) name|
|14px (what is this?)|
Maropitant (trade name Cerenia in the US and other countries), used as maropitant citrate (USAN), is a neurokinin (NK1) receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats.
Maropitant also has anti-nociceptive (analgesic) properties. In a 2012 study, parenteral maropitant decreased the minimum alveolar concentration (MAC) of sevoflurane in a pain-response model. Epidural administration had no effect. It has also been shown to decrease the MAC of sevoflurane in a cat spay and dog spay model. Whether it has analgesic properties in awake animals remains to be proven, but anecdotal evidence indicates that it is being used for analgesia by many veterinarians.
- Cerenia: Official Page
- Cerenia: Product Information at Vet Label
- FDA: Adverse Drug Experience (ADE) Reports: See Maropitant (multiple sections, p. 121-152)
- Boscan P, Monnet E, Mama K et al. (2011). "Maropitant an NK-1 Antagonist Decreases the Anesthetic Requirements During Visceral Stimulation of the Ovary in Dogs". Am J Vet Res 72: 1576–1579.
- Boscan P, Monnet E, Mama K et al. (2011). "A dog model to study ovary, ovarian ligament and visceral pain". Veterinary Anesthesia and Analgesia 38: 260–266.
- Niyom S, Boscan P, Twedt DC et al. (2013). "Effect of maropitant, a neurokinin-1 receptor antagonist, on the minimum alveolar concentration of sevoflurane during stimulation of the ovarian ligament in cats". Vet Anaesth Analg. 40: 425–431.